SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Sulperazon

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed; first approved in the 1980s.
Why 3/10
Sulperazon is an already-approved, marketed antibiotic with no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next 12 months. It is a mature, off-patent product that represents a negligible portion of Pfizer's $62B+ annual revenue, so no single event is likely to drive a material share-price move.
Actionable Insight NEUTRAL

Sulperazon is a mature, off-patent antibiotic with no upcoming regulatory catalysts or clinical readouts. For Pfizer investors, this drug is not a material value driver; the stock's performance will be determined by Pfizer's pipeline (vaccines, oncology, mRNA) and overall revenue trends, not this legacy product.

Price Chart

Loading chart...

Executive Summary

Sulperazon is Pfizer's brand name for cefoperazone/sulbactam, a combination antibiotic used to treat serious bacterial infections. It is an already-approved, off-patent product that has been on the market for decades and is sold primarily outside the United States (the individual component cefoperazone was discontinued in the US). The global market for Sulperazon is estimated at roughly $477-730 million annually, a tiny fraction of Pfizer's $62+ billion in total revenue. There are no pending regulatory decisions, pivotal clinical readouts, or other binary catalysts for this drug. For a Pfizer investor, Sulperazon is a mature legacy product with steady but unexciting dynamics and essentially zero impact on the stock's trajectory.

How It Works

Sulperazon is a combination of two drugs: cefoperazone (a cephalosporin antibiotic that kills bacteria by disrupting their cell wall construction) and sulbactam (a beta-lactamase inhibitor that prevents bacteria from breaking down the antibiotic). Together, they treat a range of bacterial infections including urinary tract, respiratory, intra-abdominal, and skin infections.

Trial Status

Sulperazon is an approved, marketed drug. No new clinical trials for this combination were found in the SecBot pipeline database for the past year. Academic research continues on optimized dosing regimens, but no registrational or pivotal trials are underway.

The Two-Sided Case

▲ Bull Case4
Sulperazon remains a trusted antibiotic in many Asian, South American, and European markets where it is still actively prescribed for serious bacterial infections.
The global Sulperazon market is projected to grow at a 4-6% CAGR through the mid-2030s, driven by rising bacterial infection rates in emerging markets.
Pfizer's established manufacturing and distribution infrastructure for sterile injectables provides a competitive moat for this product in its active markets.
The drug is listed on the WHO Essential Medicines list and continues to be studied in academic research for optimized dosing regimens.
▼ Bear Case4
Sulperazon (cefoperazone) is not available in the US market; the individual component Cefobid was discontinued in the US, limiting the drug's addressable market.
As an off-patent, mature antibiotic, Sulperazon faces generic competition in many international markets, pressuring pricing and margins.
The global Sulperazon market is estimated at roughly $477-730 million annually, a negligible fraction of Pfizer's $62+ billion total revenue, meaning even a complete loss of the product would barely move Pfizer's stock.
Antimicrobial resistance is reducing the clinical utility of older antibiotics like cefoperazone/sulbactam over time.

Upcoming Catalysts

  • No upcoming regulatory or clinical catalysts identified for Sulperazon specifically.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 8

Hover a chip for the title
1 en.wikipedia.org2 labeling.pfizer.com3 wellhn.com4 cognitivemarketresearch.com5 dataintelo.com6 en.wikipedia.org7 stockanalysis.com8 link.springer.com